Roperst.francis Physicians Partners Primary Care-durst Family Medicine Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 306 Station 22 1/2 St, Sullivans Island, SC 29482 Phone: 843-883-3176 Fax: 843-883-3459 |
Durst Family Medicine Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 306 Station 22 12, Sullivans Island, SC 29482 Phone: 843-883-3176 Fax: 843-883-3459 |
Durst Family Medicine Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 306 Station 22 1/2 St, Sullivans Island, SC 29482 Phone: 843-883-3176 Fax: 843-883-3459 |
News Archive
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced today the launch of the novel volatile atmospheric chemical ionization source for gas phase sample analysis with no additional sample preparation.
Eldorado, a division of MphasiS, an HP Company and a leading provider of health benefit and claims management platforms, today announced that American Postal Workers Union Health Plan, the fourth-largest national health insurance plan in the Federal Employees Health Benefits Program, serving more than 84,000 postal, retirees and their families, went live with ELDORADO's state-of-the-art JavelinaTM solution.
Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.
Exposing patients with chronic sinus disease to allergens and then obtaining repeated images by X-ray or ultrasound reveals that nasal allergies may be involved in some cases of chronic sinus disease, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.
› Verified 1 days ago